GHK-Cu is a small peptide bound to copper. The peptide is GHK, three amino acids long: glycine, histidine and lysine. It binds copper(II) tightly, and the copper-bound form is called GHK-Cu. GHK was first described in 1973 by Loren Pickart, who isolated it from human serum. It has been studied for more than 50 years, mostly in skin and tissue models.
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Structure
| Property | Value |
|---|---|
| Sequence | Gly-His-Lys (GHK), complexed with copper(II) |
| Length | 3 amino acids (tripeptide) |
| Molecular formula (GHK peptide) | C₁₄H₂₄N₆O₄ |
| Molecular weight (GHK peptide) | ~340.4 g/mol |
| Molecular formula (GHK-Cu, 1:1 complex, PubChem) | C₁₄H₂₃CuN₆O₄⁺ |
| Molecular weight (GHK-Cu, 1:1 complex, PubChem) | ~402.9 g/mol |
| CAS (GHK-Cu) | 89030-95-5 |
| Other names | Copper tripeptide-1 (cosmetic ingredient name), prezatide copper, copper peptide |
Published formulas and weights for GHK-Cu vary. Sources may describe the complex in different ways, or include the salt form (for example acetate). Check which form a paper or COA refers to before comparing numbers. GHK-Cu powder is usually blue, because of the copper.
What research has looked at
The largest body of work comes from Pickart and colleagues, alongside cosmetic-science and wound-healing groups. Most of it uses cell cultures and animals, plus small studies of topical products on skin. The main areas are:
- Skin and connective-tissue models. Collagen, elastin and glycosaminoglycan production by skin fibroblasts in culture. This is the most-studied area, and the reason GHK-Cu is used as a cosmetic ingredient.
- Wound models. Wound closure, blood-vessel formation and tissue remodeling in animal models. A 2026 review in Pharmaceutics calls the preclinical evidence here consistent.
- Gene-expression studies. Database analyses suggest GHK is linked to changes in the activity of many genes. These are computational and cell-based findings, not proof of effects in living organisms.
- Formulation and delivery. Hydrogels, nanoparticles and patches that carry GHK-Cu, and how stable the copper complex stays in them.
Limits of the evidence
- Most data are preclinical (cell and animal models). 2026 reviews describe clinical evidence as sparse and below current quality standards. One small human study after laser treatment (13 participants) found no effect on its objective measures.
- Human skin studies are often small, short, industry-sponsored, or use multi-ingredient products. That makes it hard to tell what GHK-Cu itself did.
- A few new human studies were registered on ClinicalTrials.gov in 2025–2026. As of November 2026, we found no published results from them.
- GHK-Cu is not approved by the FDA as a drug.
- GHK-Cu is not named on the World Anti-Doping Agency’s 2026 prohibited list. The list has a catch-all class (S0) for substances not approved for human use. We could not find an official ruling on whether that class covers GHK-Cu.
Researchers should read the primary literature directly. PubMed lists the original studies under “GHK-Cu” and “GHK copper”.
Forms OmegAmino supplies
| Form | Amount |
|---|---|
| Lyophilized powder | 50 mg vial |
| In blends | GLOW (with BPC-157 and TB-500) |
Every batch is third-party tested for identity and purity. You can look up the Certificate of Analysis for the GHK-Cu we supply at omegamino-coas.com. Read more about how we test.
Storage
Store lyophilized peptide sealed and refrigerated, kept cool, dark and away from moisture. We don’t recommend home freezers: their defrost cycles warm and cool the contents repeatedly, which can damage peptides. Once reconstituted, keep the solution refrigerated and use it within the period your protocol specifies.
Related research
- BPC-157, studied with GHK-Cu in the GLOW blend
- TB-500
- KPV
- All research overviews
Researchers with an approved account can order from the shop.
